7 April 2020
Clin-e-Cal Rafi-Tone App listed in the COVID19 Health App Formulary
GM&C Life Sciences Fund porfolio company Clin-e-Cal has been listed in the COVID19 Health App Formulary as a trusted digital solution for health management by ORCHA (The Organisation for the Review of Care and Health Apps). As an asthma management and medication adherence...
1 April 2020
OBT achieves further milestone in Boehringer Ingelheim collaboration
The Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform … OBT receives milestone payment associated with advance of drug candidate …...
31 March 2020
MicroBioSensor - New device for treatment of peritonitis undergoes clinical trials
A trial of a medical device which could improve the diagnosis and treatment of peritonitis for patients undergoing peritoneal dialysis, has started in ten major hospitals across the UK. The QuickCheck device has been developed by MicroBioSensor over the past five years in...
18 March 2020
The AMR Centre signs agreement with Microbiotix to co-develop treatment for gonorrhoea
The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical company Microbiotix, Inc. to progress a novel treatment to tackle the bacterium that is responsible for gonorrhoea. This innovative project...
12 March 2020
Blueberry Therapeutics announces new Clinical Science Lead
Blueberry Therapeutics are delighted to welcome Kerry Nield as Clinical Science Lead, with responsibility for clinical trial design and pipeline implementation including clinical scientific expertise, clinical strategy and product development planning. Kerry has over 17...
25 February 2020
Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease
Dr Alex Gibson, Business Development Officer at Cytox discusses in MedNous how to predict a person’s genetic risk of developing Alzheimer's using Polygenic Risk Scores. First application is identifying patients most suitable to enter clinical trials, based on risk of...
19 February 2020
Rinicare receives funding support from Innovate UK
Rinicare and The University Hospitals of Morecambe Bay NHS Trust are delighted to announce that they have received funding support from Innovate UK to proceed with a joint research project that will collect real-life evidence of the benefits of Rinicare’s SAFE (System to...
13 February 2020
Catapult invests in Biohabit through the GM&C Life Sciences Fund
Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund. Biohabit are developing a salivary test for the diagnosis of heart failure, which hopes to replace the need for existing blood tests. By...
28 January 2020
Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
Blueberry Therapeutics has received an investigational new drug (IND) clearance from the Food and Drug Administration (FDA) to proceed with the clinical development of BB2603 for the treatment of onychomycosis. The IND is a crucial milestone in the continued development of...
15 January 2020
Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors
Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent N on- E xecutive D irector , strengthening its strategic, financial and therapeutic expertise . Dr . Howd has over 20 years’ experience...